Clinical Trial Update: Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas [Phase 2]

View source ↗

Summary

Phase II trial of irinotecan hydrochloride in recurrent anaplastic astrocytoma, mixed malignant glioma, and oligodendroglioma was terminated; results have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioma
• Oligoastrocytoma
• Oligodendroglioma

Drugs mentioned

• IRINOTECAN HYDROCHLORIDE (irinotecan hydrochloride)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Astrocytoma, Glioma | Phase 2 | Status: TERMINATED | Results posted: 2011-12-09